Small-molecule drug development
Develops orally available drugs that modulate RNAs encoding disease targets.
Source: LinkedIn company description · Retrieved October 13, 2026
Wayfinder Biosciences develops orally available small-molecule drugs that modulate RNAs encoding disease targets.
The company combines screening and computational technologies to discover RNA-targeting small molecules. Its programs focus on traditionally inaccessible targets in oncology and neurodegenerative disease.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
Develops orally available drugs that modulate RNAs encoding disease targets.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 19, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.